Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress
Autonomix Medical, Inc. (NASDAQ: AMIX) announced that its technology and interim clinical trial findings will be featured in a podium presentation at the 2024 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress. The presentation, titled 'Rethinking pain management: transforming patient outcomes with precision mapping technology and celiac nerve RF ablation in end stage cancer', will be given by Dr. Askar Sabirov, the primary investigator for the company's ongoing proof-of-concept human clinical trial in pain associated with pancreatic cancer.
The presentation will take place on September 16th, 2024, as part of the 'Future AI Applications in Interventional Radiology' session. Autonomix CEO Brad Hauser emphasized the importance of engaging with the scientific community and aligning data release with their publication strategy to raise awareness for their innovative platform technology.
Autonomix Medical, Inc. (NASDAQ: AMIX) ha annunciato che la sua tecnologia e i risultati intermedi degli studi clinici saranno presentati in un intervento al Congresso Annuale della Società Cardiovascolare e Radiologica Interventistica d'Europa (CIRSE) del 2024. La presentazione, intitolata 'Ripensare la gestione del dolore: trasformare gli esiti dei pazienti con tecnologia di mappatura di precisione e ablazione RF del nervo celiaco nel cancro in fase terminale', sarà tenuta dal Dr. Askar Sabirov, ricercatore principale per lo studio clinico umano in corso dell'azienda sul dolore associato al cancro pancreatico.
L'intervento si terrà il 16 settembre 2024, come parte della sessione 'Future AI Applications in Interventional Radiology'. Il CEO di Autonomix, Brad Hauser, ha sottolineato l'importanza di interagire con la comunità scientifica e di allineare il rilascio dei dati con la loro strategia di pubblicazione per aumentare la consapevolezza sulla loro innovativa tecnologia di piattaforma.
Autonomix Medical, Inc. (NASDAQ: AMIX) anunció que su tecnología y los hallazgos interinos de ensayos clínicos se presentarán en una conferencia en el Congreso Anual de la Sociedad Europea de Radiología Intervencionista y Cardiovascular (CIRSE) de 2024. La presentación, titulada 'Repensando la gestión del dolor: transformando los resultados de los pacientes con tecnología de mapeo de precisión y ablación de RF del nervio celíaco en cáncer en etapa terminal', será realizada por el Dr. Askar Sabirov, investigador principal del estudio clínico humano en curso de la empresa sobre el dolor asociado al cáncer de páncreas.
La presentación se llevará a cabo el 16 de septiembre de 2024, como parte de la sesión 'Future AI Applications in Interventional Radiology'. El CEO de Autonomix, Brad Hauser, enfatizó la importancia de interactuar con la comunidad científica y alinear la divulgación de datos con su estrategia de publicación para aumentar la conciencia sobre su innovadora tecnología de plataforma.
Autonomix Medical, Inc. (NASDAQ: AMIX)는 자사의 기술 및 중간 임상 시험 결과가 2024년 유럽 심혈관 및 인터벤션 방사선학회(CIRSE) 연례 학술 대회에서 발표될 것이라고 발표했습니다. 발표 제목은 '통증 관리 재고: 말기 암에서 정밀 맵핑 기술과 췌장신경 RF 절제를 통한 환자 결과 혁신'이며, 췌장암 관련 통증에 대한 회사의 진행 중인 개념 증명 인간 임상 시험의 주요 연구자인 아스카르 사비로프 박사가 발표할 예정입니다.
발표는 2024년 9월 16일 '인터벤션 방사선학에서의 미래 AI 응용' 세션의 일환으로 진행됩니다. Autonomix의 CEO인 브래드 하우저는 과학 커뮤니티와의 소통의 중요성과 데이터 공개를 자사의 출판 전략에 맞추는 것이 혁신적인 플랫폼 기술에 대한 인식을 높이는 데 얼마나 중요한지를 강조했습니다.
Autonomix Medical, Inc. (NASDAQ: AMIX) a annoncé que sa technologie et les résultats intermédiaires d'essais cliniques seront présentés lors d'une conférence au Congrès Annuel de la Société Européenne de Radiologie Interventionnelle et Cardiovasculaire (CIRSE) en 2024. La présentation, intitulée 'Repensons la gestion de la douleur : transformer les résultats des patients avec une technologie de cartographie de précision et une ablation par RF du nerf cœliaque dans les cancers en phase terminale', sera faite par le Dr. Askar Sabirov, investigateur principal de l'essai clinique humain en cours de l'entreprise sur la douleur associée au cancer du pancréas.
La présentation aura lieu le 16 septembre 2024 dans le cadre de la session 'Future AI Applications in Interventional Radiology'. Le PDG d'Autonomix, Brad Hauser, a souligné l'importance d'engager le dialogue avec la communauté scientifique et d'harmoniser la publication des données avec leur stratégie de publication pour sensibiliser à leur technologie de plateforme innovante.
Autonomix Medical, Inc. (NASDAQ: AMIX) gab bekannt, dass ihre Technologie und die Zwischenergebnisse klinischer Studien in einer Podiumspräsentation auf dem jährlichen Kongress der Europäischen Gesellschaft für Kardiovaskuläre und Interventionelle Radiologie (CIRSE) 2024 vorgestellt werden. Die Präsentation mit dem Titel 'Schmerzkontrolle neu denken: Patientenoutcomes durch präzise Mapping-Technologie und RF-Ablation des celiakalen Nerven bei fortgeschrittenem Krebs transformieren' wird von Dr. Askar Sabirov, dem Hauptforscher der laufenden Machbarkeitsstudie des Unternehmens zu schmerzhaften Beschwerden bei Bauchspeicheldrüsenkrebs, gehalten.
Die Präsentation findet am 16. September 2024 als Teil der Sitzung 'Zukünftige KI-Anwendungen in der Interventionellen Radiologie' statt. Der CEO von Autonomix, Brad Hauser, betonte die Wichtigkeit, mit der wissenschaftlichen Gemeinschaft in Kontakt zu treten und die Datenveröffentlichung mit ihrer Publikationsstrategie in Einklang zu bringen, um das Bewusstsein für ihre innovative Plattformtechnologie zu schärfen.
- Acceptance for presentation at a prestigious global congress (CIRSE)
- Inclusion in CIRSE's new interactive area SPHAIRE, dedicated to emerging technologies in Interventional Radiology
- Opportunity to showcase interim clinical trial findings and technology to the scientific community
- None.
Presentation to discuss latest developments in future AI applications in interventional radiology, specifically highlighting the early results from the Company’s ongoing proof-of-concept (PoC) human clinical trial
THE WOODLANDS, TX, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced its technology and interim clinical trial findings will be featured in a podium presentation at the 2024 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress being held September 14-18, 2024 in Lisbon, Portugal.
“As we continue to execute on our clinical strategy, engaging with the scientific community is a priority and area of focus for Autonomix. We are thrilled to have received acceptance for presentation at this prestigious global congress and to be included in CIRSE’s newly added, state-of-the art interactive area, called SPHAIRE, which is dedicated to deepening the understanding of what emerging technologies can bring to Interventional Radiology. We believe aligning the release of our data and our publication strategy is a key component of raising awareness for our innovative platform technology, and we look forward to participating in this upcoming event,” commented Brad Hauser, Chief Executive Officer of Autonomix.
Details of the presentation are as follows:
Title: Rethinking pain management: transforming patient outcomes with precision mapping technology and celiac nerve RF ablation in end stage cancer
Session: Future AI Applications in Interventional Radiology
Presenter: Dr. Askar Sabirov, Primary Investigator for the Company’s ongoing PoC human clinical trial in pain associated with pancreatic cancer
Session Date and Time: Monday, September 16th from 11:15 AM – 12:15 PM ET
For more information about the CIRSE Annual Congress, please visit the event website here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that can detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” “can,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on May 31, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com
FAQ
What is the title of Autonomix Medical's presentation at the 2024 CIRSE Annual Congress?
Who will be presenting Autonomix Medical's (AMIX) findings at the 2024 CIRSE Annual Congress?
When and where will Autonomix Medical (AMIX) present at the 2024 CIRSE Annual Congress?
What is the focus of Autonomix Medical's (AMIX) ongoing clinical trial mentioned in the presentation?
